Definitive benchmarking of DDA and DIA for host cell protein analysis on the Orbitrap Astral in a regulatory-aligned framework
Authors:
Preprint
Abstract
Host cell proteins (HCPs) are critical quality attributes in biotherapeutics and require accurate, protein-resolved quantification beyond the coverage limits of immunoassays. The Orbitrap Astral mass spectrometer was evaluated for label-free HCP analysis through a direct comparison of data-dependent acquisition (DDA, Top80) and data-independent acquisition (DIA, 4 m/z windows). Deterministic protein inference was implemented to ensure invariant protein grouping across datasets and software versions. Quantification was anchored using a whole-proteome stable isotope–labeled HCP standard, with identification error controlled through empirical false discovery proportion estimation. Both acquisition modes quantified total HCP content with high linearity (R 2 > 0.99) and total error within ±30% acceptance limits across a seven-point spike-in series. DIA achieved greater analytical depth, identifying 45% more proteins and 68% more peptides than DDA, with substantially reduced missingness. Protein-level fold-change behavior was evaluated using hierarchical Bayesian regression, with slopes centered near unity for DIA and systematic compression observed for DDA. Abundance-stratified resampling analysis demonstrated trueness and precision across the dynamic range and defined lower limits of quantification of approximately 0.6 ppm for DIA and 1.6 ppm for DDA. Both acquisition strategies accurately report global HCP content, while DIA provides improved coverage, fold-change fidelity, and sensitivity for low-abundance impurities. This study demonstrates that untargeted MS-based HCP measurements can be analytically qualified for use in regulated biopharmaceutical settings.Keywords
All Related Versions
- Published version: Journal of Pharmaceutical and Biomedical Analysis Open, 7.
This publication has 67 references indexed in Scilit:
- “High‐risk” host cell proteins (HCPs): A multi‐company collaborative viewBiotechnology and Bioengineering, 2021
- Mass spectrometric evaluation of upstream and downstream process influences on host cell protein patterns in biopharmaceutical productsBiotechnology Progress, 2019
- Cathepsin L Causes Proteolytic Cleavage of Chinese‐Hamster‐Ovary Cell Expressed Proteins During Processing and Storage: Identification, Characterization, and MitigationBiotechnology Progress, 2018
- Experience with host cell protein impurities in biopharmaceuticalsBiotechnology Progress, 2018
- Proteomics in biomanufacturing control: Protein dynamics of CHO‐K1 cells and conditioned media during apoptosis and necrosisBiotechnology and Bioengineering, 2018
- Effects of lysosomal biotherapeutic recombinant protein expression on cell stress and protease and general host cell protein release in Chinese hamster ovary cellsBiotechnology Progress, 2017
- Knockout of a difficult‐to‐remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulationsBiotechnology and Bioengineering, 2016
- Carboxypeptidase D is the only enzyme responsible for antibody C‐terminal lysine cleavage in Chinese hamster ovary (CHO) cellsBiotechnology and Bioengineering, 2016
- Host cell proteins in biotechnology‐derived products: A risk assessment frameworkBiotechnology and Bioengineering, 2015
- Host cell protein testing by ELISAs and the use of orthogonal methodsBiotechnology and Bioengineering, 2014